Navigation Links
Ondine Biopharma Announces Second Quarter 2008 Financial Results
Date:8/14/2008

VANCOUVER, Aug. 14 /PRNewswire-FirstCall/ - Ondine Biopharma Corporation (the "Company" or "Ondine", TSX: OBP; AIM: OBP) a medical technology company developing photodisinfection based products, today announced its financial results for the second quarter ended June 30, 2008.

"During the past quarter we made significant regulatory and clinical progress with our photodisinfection technology and we are leveraging our successes to advance discussions with prospective strategic partners," stated Carolyn Cross, Ondine's President & CEO, "We also took steps to build on our technology as we see the opportunity to address many unmet medical needs with our photodisinfection platform. Accordingly, having validated Periowave (TM) in the Canadian dental market, we are refocusing our resources on new product development and obtaining appropriate strategic partners for the commercialization and co-development of our photodisinfection-based product pipeline."

2008 Second Quarter Results and Recent Developments

FINANCIAL RESULTS

For the quarter ended June 30, 2008 (the "Second Quarter of 2008"), the Company recorded a loss of $2.43 million or $0.04 per common share compared with a loss of $3.79 million or $0.07 per common share during the quarter ended June 30, 2007 (the "Second Quarter of 2007"). For the six months ended June 30, 2008 (the "First Half of 2008"), the Company recorded a loss of $4.9 million or $0.08 per common share compared with a loss of $7.24 million or $0.13 per common share during the six months ended June 30, 2007 (the "First Half of 2007"). Product sales of our laser base stations and treatment kits during the Second Quarter of 2008 amounted to $0.26 million with a gross margin of $0.18 million (69.8%) compared to product sales of $0.51 million and a gross margin of $0.23 million (45.6%) during the Second Quarter of 2007. Product sales of our laser base stations and treatment kits during the First Half of 2008 amounted
'/>"/>

SOURCE Ondine Biopharma Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. Ondine to Present at Canaccord Adams 28th Annual Global Growth Conference
2. Ondine Announces Publication of Positive Results from Pseudomonas aeruginosa Eradication Study
3. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. PDL BioPharma Announces Internal CEO Investigation Found No Credible Evidence of Improper Personal Conduct or Breach of Fiduciary Duty
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development
8. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
9. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
10. Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG
11. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 30, 2014 Whitehouse Laboratories ... by the Parenteral Drug Association (PDA) to ... 2014) on container closure integrity testing. This lecture/laboratory course ... methods and philosophies detailed in the recently proposed revision ... The course will span container closure integrity testing ...
(Date:9/30/2014)... MA and Pittsburgh PA (PRWEB) September 30, 2014 ... Clinical Research Nurses ( IACRN), a non-profit ... Alliance for Clinical Research Excellence and Safety ... the signing of a strategic alliance agreement, setting ... IACRN’s vision is to enhance clinical research quality ...
(Date:9/29/2014)... forefront of diagnostics today, with imaging techniques like ... and NMR (nuclear magnetic resonance) increasing steeply over ... image resolution and quality still limit these techniques ... solution is hyperpolarization, which involves injecting the patient ... following the distribution and fate of specific molecules ...
(Date:9/29/2014)... Sept. 29, 2014  Ten of the most ... cartilage repair, regeneration, allograft reconstruction and research and ... world gathered to discuss the future of cartilage ... Regenerative Medicine symposium, Cartilage Regeneration: State of ... Orthopedic Biosurgery, Minced Juvenile Allograft, and State of ...
Breaking Biology Technology:Whitehouse Laboratories to Partner with PDA for Educational Course on Container Closure Integrity Testing 2Whitehouse Laboratories to Partner with PDA for Educational Course on Container Closure Integrity Testing 3Whitehouse Laboratories to Partner with PDA for Educational Course on Container Closure Integrity Testing 4IACRN and ACRES to Support Clinical Research Nurses 2IACRN and ACRES to Support Clinical Research Nurses 3A safer approach for diagnostic medical imaging 2A safer approach for diagnostic medical imaging 3World Renowned Experts Discuss Future Of Cartilage Regeneration 2World Renowned Experts Discuss Future Of Cartilage Regeneration 3
... (Nasdaq: AMLN ) issued the following statement ... Eastbourne Capital Management, L.L.C., made public earlier today:"After significant ... unable to achieve a settlement with Eastbourne and Carl ... shareholders. Of course, we continue to remain open to ...
... ATLANTA, May 20 Germany will present itself ... locations at this year,s BIO,International Convention. Under the ... will provide invaluable insight into the,latest research results ... The,German research landscape and the regulatory framework conditions ...
... N.C., May 20 Asymchem Laboratories, Inc., a leading ... Products to the pharmaceutical industry, with sites in ... the recent addition of Dr. Chris Huber as ... the table over 15 years experience in the ...
Cached Biology Technology:Amylin Responds to Eastbourne Letter 2Amylin Responds to Eastbourne Letter 3Amylin Responds to Eastbourne Letter 4BIO International Convention 2009: Research Location Germany Presents Potential in Regenerative Medicine 2Dr. Chris Huber Joins Asymchem Laboratories Inc. as Director of Chemical Development 2
(Date:9/30/2014)... The New England Journal of Medicine reports ... the drug crizotinib against the subset of lung cancer ... multi-center study of 50 patients with advanced non-small cell ... response rate was 72 percent, with 3 complete responses ... time it takes for the disease to resume its ...
(Date:9/30/2014)... (LMU) in Munich report that a new class ... to chemotherapeutic drugs. They have also pinpointed the ... for anti-tumor agents. , Researchers led by ... of the Technische Universitt Mnchen have identified a ... weapon in the fight against malignant tumors. The ...
(Date:9/30/2014)... of perilous threats in today,s ocean. From overfishing ... fragile coral ecosystems are disappearing at unprecedented rates ... of corals surrounding the island of Moorea in ... tropical environment: coral guard-crabs. New research from the ... scientist Seabird McKeon and the museum,s predoctoral fellow ...
Breaking Biology News(10 mins):NEJM: Crizotinib effective in Phase 1 trial against ROS1 lung cancer 2Cancer therapy: Driving cancer cells to suicide 2Smithsonian scientists discover coral's best defender against an army of sea stars 2
... recent study led by scientists from the National University of ... Spinal Muscular Atrophy (SMA), a devastating disease that is the ... young adults. As there is currently no known cure for ... fight against SMA. SMA is caused by deficiencies ...
... , Dec. 18, 2013 Tissue engineering ... a regenerative or reparative medicine with potential to ... engineering, which involve leveraging technologies from biomaterials, molecular ... the restructure and/or repair of human organs through ...
... have shown for the first time that the specialised role ... cilia tiny hair-like structures protruding from a cell. Stem ... body through the process of differentiation. The discovery ... therapies for a range of medical treatments where scientists aim ...
Cached Biology News:Study led by NUS scientists provides new insights into cause of human neurodegenerative disease 2Study led by NUS scientists provides new insights into cause of human neurodegenerative disease 3State-of-the-Art Tissue Engineering and Organ Regeneration Technologies Yield Healthcare Market Disruption 2State-of-the-Art Tissue Engineering and Organ Regeneration Technologies Yield Healthcare Market Disruption 3State-of-the-Art Tissue Engineering and Organ Regeneration Technologies Yield Healthcare Market Disruption 4
Features , Designed to assist users in applying domed caps to tube strips and plates , Minimises the pressure required to seal the caps effectively , Enables multiple tubes to be sealed simultaneousl...
Lysozyme C (W-20)...
... and BR4i refrigerated multifunction centrifuges are equally capable ... a low sound level with a large range ... AUTO-LOCK rotor exchange system without tools ensures that ... seconds. Instant rotor exchange (5 sec.) ...
... X-Gal (5-bromo-4-chloro-3-indoyl-beta-D-galactopyranoside) is a ... identify recombinant plasmids. In ... and IPTG, lac ... blue, whereas recombinant colonies ...
Biology Products: